Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid?

European Journal of Surgical Oncology

Volumn 34, Issue 3, 2008, Pages 256-262

  Schwartz, M E ^a   D'Amico, F ^b   Vitale, A ^c   Emre, S ^a   Cillo, U ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Milan criteria

Indexed keywords

ACCURACY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; DIAGNOSTIC ACCURACY; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; RESOURCE ALLOCATION; REVIEW; SCORING SYSTEM; TREATMENT INDICATION;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; TISSUE AND ORGAN PROCUREMENT;

EID: 39749106013     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.07.208     Document Type: Review

References (106)

1. El-Serag H.B., Davila J.A., Petersen N.J., and McGlynn K.A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139 (2003) 817
2. Davila J.A., Morgan R.O., Shaib Y., et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127 (2004) 1372
3. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusion of the Barcelona - 2000 EASL conference. J Hepatol 35 (2001) 421-430
4. Bruix J., and Llovet J.M. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35 (2002) 519-524
5. Befeler A.S., and Di Bisceglie A.M. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122 (2002) 1609-1619
6. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907
7. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208
8. Iwatsuki S., Gordon R.D., Shaw B.W., and Starzl T.E. Role of liver transplantation in cancer therapy. Ann Surg 202 (1985) 401-407
9. O'Grady J.G., Polson R.J., Rolles K., et al. Liver transplantation for malignant disease: results in 93 consecutive patients. Ann Surg 207 (1988) 373-379
10. Olthoff K.M., Millis J.M., Rosove M.H., et al. Is liver transplantation justified for the treatment of hepatic malignancies?. Arch Surg 125 (1990) 1261-1268
11. Bismuth H., Chiche L., Adam R., et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 218 (1993) 145-151
12. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
13. Llovet J.M., Bruix J., Fuster J., et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 27 (1998) 1572-1577
14. UNOS/OPTN policy 3.6.4.4. Available at:. [accessed 15.01.05]
15. Cillo U., Vitale A., Bassanello M., et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 239 (2004) 150-159
16. Yao F.Y., Ferrel L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33 (2001) 1394-1403
17. Kaihara S., Kiuchi T., Ueda M., et al. Living-donor liver transplantation for hepatocellular carcinoma. Transplantation 75 (2003) S37-S40
18. Sotiropoulos G.C., Malagò M., Molmenti E., et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic?. Transplantation 79 (2005) 483-487
19. Shah S.A., Tan J.C.C., McGilvray I.D., et al. Accuracy of staging as a predictor of recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 81 (2006) 1633-1639
20. Pawlik T.M., Delman K.A., Vauthey J.N., et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 11 (2005) 1086-1092
21. Kirimlioglu H., Dvorchick I., Ruppert K., et al. Hepatocellular carcinomas in native livers from patients with orthotopic liver transplantation: biologic and therapeutic implications. Hepatology 34 (2001) 502-510
22. Jonas S., Bechstein W.O., Steinmuller T., et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33 (2001) 1080-1086
23. Zavaglia C., De Carlis L., Alberti A.B., et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 100 (2005) 2708-2716
24. Klintmalm G.B. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of the tumor characteristics on outcome. Ann Surg 228 (1998) 479-490
25. Molmenti E., and Klintmalm G. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl 8 (2002) 736-748
26. Herrero J.L., Sangro B., Quiroga J., et al. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 7 (2001) 631-636
27. Roayaie S., Frischer J.S., Emre S.H., et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235 (2002) 533-539
28. Salizzoni M., Zamboni F., Lupo F., et al. Liver transplantation for early-detected, multifocal hepatocellular carcinoma. Br J Surg 88 (2001) 1194-1195
29. Goodman J., Glasgow S.C., Schnitzler M., et al. Liver transplantation for hepatocellular carcinoma. Expanding special priority to include stage III disease. Arch Surg 140 (2005) 459-464
30. Marsh J.W., Dvorchik I., Subotin M., et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology 26 (1997) 444-450
31. Iwatsuki S., Dvorchik I., Marsh J.W., et al. Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 191 (2000) 389-394
32. Marsh J.W., Dvorchik I., Bonham C.A., and Iwatsuki S. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?. Cancer 88 (2000) 538-543
33. Marsh J.W., and Dvorchik I. Liver organ allocation for hepatocellular carcinoma: are we sure?. Liver Transpl 9 (2003) 693-696
34. Yao F.Y., Ferrel L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 8 (2002) 765-774
35. Todo S., and Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 240 (2004) 451-461
36. Tamura S., Kato T., Berho M., et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 136 (2001) 25-30
37. Esnaola N.F., Lauwers G.Y., Mirza N.Q., et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 6 (2002) 224-232
38. Park N.H., Chung Y.H., Youn K.H., et al. Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma. J Clin Gastroenterol 33 (2001) 397-401
39. Lauwers G.Y., Terris B., Balis K.P., et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic index. Am J Surg Pathol 26 (2002) 25-34
40. Vauthey J.N., Lauwers G.Y., Esnaola N.F., et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 20 (2002) 1527-1536
41. Margarit C., Charco R., Hidalgo E., et al. Liver transplantation for malignant disease: selection and pattern of recurrence. World J Surg 26 (2002) 257-263
42. Hemming A.W., Cattral M.S., Reed A.I., et al. Liver transplantation for hepatocellular carcinoma. Ann Surg 233 (2001) 652-659
43. Yamanaka J., Yamanaka N., Nakasho K., et al. Clinicopathologic analysis of stage II-III hepatocellular carcinoma showing early massive recurrence after liver resection. J Gastrenterol Hepatol 15 (2000) 1192-1198
44. Llovet J.M., Fuster J., and Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30 (1999) 1434-1440
45. Yao F.Y., Bass N.M., Nikolai B., et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 8 (2002) 873-883
46. Yao F.Y., Bass N.M., Nikolai B., et al. A follow up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 9 (2003) 684-692
47. Yao F.Y., Bass N.M., Ascher N.L., and Roberts J.P. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the model of end-stage liver disease (MELD) organ allocation policy. Liver Transpl 10 (2004) 621-630
48. Llovet J.M., Bru C., and Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19 (1999) 329-338
49. Greene F.L., Page D.L., Fleming I.D., et al. AJCC cancer staging manual. 6th ed. (2002), Springer, Chicago, USA p. 131-44
50. Cillo U., Bassanello M., Vitale A., et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?. J Hepatol 40 (2004) 124-131
51. Cillo U., Vitale A., Grigoletto F., et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 44 (2006) 723-731
52. Okuda K., Othtsuki T., Obata H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 56 (1985) 918-928
53. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28 (1998) 751-755
54. Chevret S., Trinchet J.C., Mathieu D., Rached A.A., Beaugrand M., and Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 31 (1999) 133-141
55. Leung T.W., Tang A.M., Zee B., et al. Construction of the Chinese University prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, the Cancer of the Liver Italian Program staging system. Cancer 94 (2002) 1760-1769
56. Marrero J.A., Fontana R.J., Barrat A., et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41 (2005) 707-716
57. The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31 (2000) 840-845
58. Kudo M., Chung H., and Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38 (2003) 207-215
59. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., and Williams R. Transection of the oesophagus for bleeding esophageal varices. Br J Surg 60 (1973) 646-664
60. Fleming I.D., Cooper J.S., Henson D.E., et al. AJCC cancer staging manual (1997), Lippincott-Raven, Philadelphia
61. Kudo M., Chung H., Haji S., et al. Validation of a new prognostic system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 40 (2004) 1396-1405
62. Adam R., Azoulay D., Castaing D., et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis. A reasonable strategy?. Ann Surg 238 (2003) 508-517
63. Majno P.E., Sarasin F.P., Mentha G., et al. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology 31 (2000) 899-906
64. Sala M., Fuster J., Llovet J.M., et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl 10 (2004) 1294-1300
65. Bassanello M., Cillo U., Vitale A., et al. Multimodal approach and its impact on survival for patients with hepatocellular carcinoma. Anticancer Res 23 (2003) 4047-4054
66. Belghiti J., Cortes A., Abdalla E.K., et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 238 (2003) 885-892 [discussion 892-893]
67. Cillo U., Vitale A., Brolese A., et al. Partial hepatectomy as first line treatment of patients with hepatocellular carcinoma. J Surg Oncol (October 25, 2006)
68. Morioka D., Tanaka K., Matsuo K., et al. Applicability of the Milan criteria for determining liver transplantation as a first-line treatment for hepatocellular carcinoma. Ann Surg Oncol (2006)
69. Sutcliffe R., Maguire D., Prtmann M., et al. Selection of patients with hepatocellular carcinoma for liver transplantation. Br J Surg 93 (2006) 11-18
70. Altimari A., Fiorentino M., Gabusi E., et al. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig Liver Dis 35 (2003) 332-338
71. El-Assal O.N., Yamanoi A., Soda Y., et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27 (1998) 1554-1562
72. Endo K., and Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol 32 (2000) 78-84
73. Endo K., Ueda T., Ueyama J., et al. Immunoreactive E-cadherin, α-catenin, β-catenin, γ-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, patients' survival. Hum Pathol 31 (2000) 558-565
74. Fiorentino M., Altimari A., D'Errico A., et al. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res 6 (2000) 3966-3972
75. Hsu H.C., Jeng Y.M., Mao T.L., et al. β-Catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B and with favourable prognosis. Am J Pathol 157 (2000) 763-770
76. Inagawa S., Itabashi M., Adachi S., et al. Expression and prognostic roles of β-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 8 (2002) 450-456
77. Ito Y., Matsuura N., Sakon M., et al. Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer 81 (1999) 747-751
78. Ito Y., Matsuura N., Sakon M., et al. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 30 (1999) 90-99
79. Kawate S., Fukusato T., Ohwada S., et al. Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression. Oncology 57 (1999) 157-163
80. Kobayashi T., Kubota K., Takayama T., and Makuuchi M. Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg 181 (2001) 284-288
81. Maatta M., Soini Y., Liakka A., and Autio-Harmainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 6 (2000) 2726-2734
82. Matsuda Y., Ichida T., Genda T., et al. Loss of p16 contributes to p27 sequestration by cyclin D(1)-cyclin dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. Clin Cancer Res 9 9 (2003) 3389-3396
83. Matsumura T., Makino R., and Mitamura K. Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin Cancer Res 7 (2001) 594-599
84. Nanashima A., Yano H., Yamaguchi H., et al. Immunohistochemical analysis of tumor biological factors in hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection. J Gastroenterol 39 2 (2004) 148-154
85. Nhieu J.T.V., Renard C.A., Wei Y., et al. Nuclear accumulation of mutated β-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 155 (1999) 703-710
86. Ohashi R., Gao C., Miyazaki M., et al. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res 21 (2001) 657-662
87. Ouchi K., Sugawara T., Ono H., et al. Mitotic index is the best predictive factor for survival of patients with resected hepatocellular carcinoma. Dig Surg 17 (2000) 42-48
88. Qin L.X., and Tang Z.Y. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 8 (2002) 385-392
89. Graziadei I.W., Sandmueller H., Waldenberger P., et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 9 (2003) 557-563
90. Maddala Y.K., Stadheim L., Andrews J.C., et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 10 (2004) 449-455
91. Vitale A., Brolese A., Zanus G., et al. Multimodal therapy before liver transplantation for hepatocellular carcinoma. Hepatol Res (January 31, 2005)
92. Lu D.S.K., Yu N.C., Raman S.S., et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 41 (2005) 1130-1137
93. Huo T.I., Lin H.C., Lee F.Y., et al. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy. Liver Transpl 10 (2004) 1507-1513
94. Yamashiki N., Tateishi R., Yoshida H., et al. Ablation therapy in containing extension of hepatocellular carcinoma: a simulative analysis of dropout from the waiting list for transplantation. Liver Transpl 11 (2005) 508-514
95. Yao F.Y., Kinkhabwala M., LaBerdge J.M., et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant 5 (2005) 795-804
96. Yao F.Y., Hirose R., LaBerge J.M., et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 11 (2005) 1505-1514
97. Otto G., Herber S., Heise M., et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 12 (2006) 1260-1267
98. Wiesner R.H., Freeman R.B., and Mulligan D.C. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 127 Suppl. 1 (2004) S261-S267
99. Schwartz M. Liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 10 2, Suppl. 1 (2004) S81-S85
100. Freeman R.B., Edwards E.B., and Harper A.M. Waiting list removal rates among patients with chronic and malignant liver disease. Am J Transplant 6 (2006) 1416-1421
101. Ravioli M., Grazi G.L., Ercolani G., et al. Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era. Transplantation 81 (2006) 525-530
102. Sotiropoulos G.C., Paul A., Momenti E., et al. Liver transplantation for hepatocellular carcinoma in cirrhosis within the Eurotransplant area: an additional option with "livers that nobody wants". Transplantation 80 (2005) 897-902
103. Gondolesi G.E., Roayaie S., Munoz L., et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 240 (2004) 451-459
104. Sarasin F.P., Majno P.E., Llovet J.M., et al. Living donor liver transplantation for early hepatocellular carcinoma: a life expectancy and cost-effectiveness perspective. Hepatology 33 (2001) 1073-1079
105. Cardillo M., De Fazio N., Pedotti P., et al. Split and whole liver transplantation outcomes: a comparative cohort study. Liver Transpl 12 (2006) 402-410
106. Marsh J.W., Finkelstein S.D., Demetris A.J., et al. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl 9 (2003) 664-671